Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway

Fig. 6

SFN enhances the antitumor ability of CAR-T cells in patients with cancer. A Time line of immunotherapy treatment. B The expression of PD-1 on CD8+ CAR-T cells derived from patients who had or had not received sulforaphane (SFN) at different time points. D, E The expression of IFN-γ and IL-2 in CD8+ CAR-T cells derived from patients who had or had not received SFN on day 2, 7, 14, and 21. *, P < 0.05; **, P < 0.01 (Student’s t test)

Back to article page